Systemic Targeting of Lymph Node Metastasis through the Blood Vascular System by Using Size-Controlled Nanocarriers

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Occult nodal metastases are linked to increased cancer recurrence and poorer patient prognosis.
• Current treatments for lymph node metastases often rely on local injections, limiting applicability.
• Systemic nanocarrier delivery offers potential for targeted metastatic disease control.

Purpose of the Study:

• To investigate the efficacy of sub-50 nm polymeric micelles for targeting lymph node metastases after systemic administration.
• To evaluate the impact of nanocarrier size on targeting efficiency and therapeutic outcomes.
• To compare the performance of small polymeric micelles with larger liposomes (Doxil).

Main Methods:

• Utilized a syngeneic melanoma model in mice.
• Administered sub-50 nm platinum-drug-loaded polymeric micelles systemically.
• Compared targeting efficiency with 70 nm micelles and 80 nm doxorubicin-loaded liposomes (Doxil).
• Assessed nanocarrier extravasation and penetration within lymph node metastases.

Main Results:

• Sub-50 nm polymeric micelles demonstrated effective targeting of lymph node metastases following systemic injection, even after primary tumor removal.
• Nanocarrier size significantly influenced targeting efficiency, correlating with extravasation and penetration capabilities.
• Smaller micelles (sub-50 nm) showed superior targeting compared to larger micelles (70 nm) and Doxil (80 nm).
• Treatment with targeted micelles limited the growth of lymph node metastases.

Conclusions:

• Sub-50 nm polymeric micelles are effective in targeting lymph node metastases via systemic administration.
• Nanocarrier size is a critical factor for successful extravasation and penetration into metastatic sites.
• These findings support the development of small polymeric micelles as a conservative therapeutic strategy for lymph node metastasis, aiming to reduce relapse and enhance survival.